Recent Quotes (30 days)

You have no recent quotes
chg | %

Sierra Oncology Inc  

(Public, NASDAQ:SRRA)   Watch this stock  
Find more results for SRRA
3.14
-0.02 (-0.63%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.06 - 3.28
52 week 1.10 - 3.41
Open 3.23
Vol / Avg. 624,232.00/557,920.00
Mkt cap 163.17M
P/E     -
Div/yield     -
EPS -0.95
Shares 52.30M
Beta     -
Inst. own 56%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -35.18% -36.30%
Return on average equity -37.11% -38.51%
Employees 53 -
CDP Score - -

Address

2150-885 Georgia St W
VANCOUVER, BC V6C 3E8
Canada
+1-604-5586536 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

Officers and directors

Donald R. Parfet Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Nicholas R. Glover Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Sukhi Jagpal Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Barbara Klencke M.D. Chief Development Officer
Age: 58
Bio & Compensation  - Reuters
Mark Kowalski M.D. Ph.D. Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Angie J. You Ph.D. Chief Business & Strategy Officer and Head of Commercial
Age: 43
Bio & Compensation  - Reuters
Andrew R. Allen M.D. Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
Jeffrey H. Cooper Independent Director
Age: 61
Bio & Compensation  - Reuters
Daniel Estes Ph.D. Independent Director
Age: 36
Bio & Compensation  - Reuters
Tran Nguyen Independent Director
Age: 43
Bio & Compensation  - Reuters